{"id":30,"date":"2022-02-28T21:19:24","date_gmt":"2022-02-28T21:19:24","guid":{"rendered":"https:\/\/hcrplatform.com\/?page_id=30"},"modified":"2022-04-19T15:25:46","modified_gmt":"2022-04-19T15:25:46","slug":"trials","status":"publish","type":"page","link":"https:\/\/hcrplatform.com\/?page_id=30","title":{"rendered":"Trials"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Platform members also participate in ongoing international clinical trials:<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
  1. Clinical Evaluation of the\u00a0<\/strong>Panbio\u2122<\/strong>COVID-19<\/strong>\/ Flu A&B Rapid Panel.<\/strong> .\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sponsor: Abbott Rapid Diagnostics Jena GmbH, Start: 01.11.2021\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kakha Nadaraia \u2013 Principal Investigator (PI)<\/strong><\/li><\/ol>

    \u00a0<\/strong><\/p>

    1. A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluating the Efficacy and Safety of Amiselimod (MT-1303) in Subjects With Mild to Moderate Ulcerative Colitis (AMUC2023) <\/strong><\/li><\/ol>

      SPONSOR: Bausch Health Americas, Inc.\u00a0 Start: 09.2021<\/p>

      Kakha Nadaraia – Subinvestigator\u00a0 <\/strong><\/p>

      \u00a0<\/strong><\/p>

      1. Alfapump\u00ae DSR Feasibility Study in Subjects with Persistent Congestion Due to Heart Failure, Resistant to Loop Diuretic Treatment (SAHARA)<\/strong><\/li><\/ol>

        Sponsor: Sequana Medical N.V.\u00a0\u00a0\u00a0 Start: 05.2021<\/p>

        Zurab Klimiashvili \u2013 Principal Investigator (PI), Tamar Shengelia \u2013 Study Coordinator <\/strong><\/p>

        \u00a0<\/p>

        1. A Randomized, Placebo-Controlled, Double-blind 52 week Study to Assess the Efficacy and safety of etrazimod in subjects With Moderately active Ulcerative Colitis <\/strong><\/li><\/ol>

          Sponsor: <\/strong>Arena Pharmaceuticals,\u00a0 Start: 19.04.2021<\/p>

          Kakha Nadaraia \u2013 Subinvestigator<\/strong><\/p>

          \u00a0<\/p>

          1. A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease<\/strong> (CULTIVATE), <\/strong><\/li><\/ol>

            Sponsor: <\/strong>Arena Pharmaceuticals, Start: 12.02.2020<\/p>

            Kakha Nadaraia \u2013 Subinvestigator<\/strong><\/p>

            \u00a0<\/p>

            1. A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel-Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin Angiotensin Aldosterone System Inhibitor (Raasi) Medications for the Treatment of Heart Failure (DIAMOND) <\/strong><\/li><\/ol>

              Sponsor:\u00a0 <\/strong>Vifor Pharma, Inc. Collaborator: <\/strong>Syneos Health, LLC, Start: 25.04.2019<\/p>

              Kakha Nadaraia – Study Coordinator and Subinvestigator<\/strong><\/p>

              \u00a0<\/p>

              1. Induction Study #1 – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease<\/strong><\/li><\/ol>

                Sponsor: Celgene,\u00a0\u00a0 Start: 27.02.2018<\/p>

                Kakha Nadaraia – Subinvestigator<\/strong><\/p>

                \u00a0<\/p>

                1. Induction Study #2 – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease<\/strong><\/li><\/ol>

                  Sponsor: Celgene,\u00a0\u00a0 Start: 07.03.2018<\/p>

                  Kakha Nadaraia \u2013 Subinvestigator<\/strong><\/p>

                  \u00a0<\/p>

                  1. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease<\/strong><\/li><\/ol>

                    Sponsor: Celgene,\u00a0\u00a0 Start: 27.06.2018<\/p>

                    Kakha Nadaraia \u2013 Subinvestigator<\/strong><\/p>

                    \u00a0<\/p>

                    1. A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease <\/strong><\/li><\/ol>

                      Sponsor: Celgene, Start: 22.08.2018<\/p>

                      Kakha Nadaraia \u2013 Subinvestigator <\/strong><\/p>

                      \u00a0<\/strong><\/p>

                      1. A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer\u00ae (Ferric\u00a0 Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency\u00a0(HEART-FID)<\/strong><\/li><\/ol>

                        Sponsor: American Regents inc.\u00a0 Start: 03.2017<\/p>

                        Zurab Klimiashvili \u2013 Principal Investigator (PI)<\/strong><\/p>

                        \u00a0<\/strong><\/p>

                        1. A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis <\/strong><\/li><\/ol>

                          Sponsor: Celgene,\u00a0 Start: 02.12. 2015<\/p>

                          Kakha Nadaraia – Cardiologist<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

                          Platform members also participate in ongoing international clinical trials: Clinical Evaluation of the\u00a0Panbio\u2122COVID-19\/ Flu A&B Rapid Panel. .\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sponsor: Abbott Rapid Diagnostics Jena GmbH, Start: 01.11.2021\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kakha Nadaraia \u2013 Principal Investigator (PI) \u00a0 A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluating the Efficacy and Safety of Amiselimod (MT-1303) in Subjects With Mild to […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"footnotes":""},"class_list":["post-30","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/hcrplatform.com\/index.php?rest_route=\/wp\/v2\/pages\/30","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hcrplatform.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/hcrplatform.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/hcrplatform.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hcrplatform.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30"}],"version-history":[{"count":7,"href":"https:\/\/hcrplatform.com\/index.php?rest_route=\/wp\/v2\/pages\/30\/revisions"}],"predecessor-version":[{"id":697,"href":"https:\/\/hcrplatform.com\/index.php?rest_route=\/wp\/v2\/pages\/30\/revisions\/697"}],"wp:attachment":[{"href":"https:\/\/hcrplatform.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}